CL2013002607A1 - Polipeptido de fusion nucleotido pirofosfatasa/fosfodiesterasa 1 (npp1) que comprende un dominio catalitico del extremo c-terminal de npp1, una región fc de una inmunoglobulina y opcionalmente un resto de direccionamiento; ácido nucleico que lo codifica; vector; celula huesped. - Google Patents
Polipeptido de fusion nucleotido pirofosfatasa/fosfodiesterasa 1 (npp1) que comprende un dominio catalitico del extremo c-terminal de npp1, una región fc de una inmunoglobulina y opcionalmente un resto de direccionamiento; ácido nucleico que lo codifica; vector; celula huesped.Info
- Publication number
- CL2013002607A1 CL2013002607A1 CL2013002607A CL2013002607A CL2013002607A1 CL 2013002607 A1 CL2013002607 A1 CL 2013002607A1 CL 2013002607 A CL2013002607 A CL 2013002607A CL 2013002607 A CL2013002607 A CL 2013002607A CL 2013002607 A1 CL2013002607 A1 CL 2013002607A1
- Authority
- CL
- Chile
- Prior art keywords
- npp1
- phosphodiesterase
- immunoglobulin
- terminus
- encodes
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 101710199133 Nucleotide pyrophosphatase/phosphodiesterase Proteins 0.000 title 1
- 230000003197 catalytic effect Effects 0.000 title 1
- 230000004927 fusion Effects 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04001—Phosphodiesterase I (3.1.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34006610P | 2010-03-12 | 2010-03-12 | |
| PCT/US2011/028233 WO2011113027A2 (en) | 2010-03-12 | 2011-03-11 | Npp1 fusion proteins |
| PCT/US2011/051858 WO2012125182A1 (en) | 2011-03-11 | 2011-09-15 | Npp1 fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013002607A1 true CL2013002607A1 (es) | 2014-03-28 |
Family
ID=44564171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013002607A CL2013002607A1 (es) | 2010-03-12 | 2013-09-10 | Polipeptido de fusion nucleotido pirofosfatasa/fosfodiesterasa 1 (npp1) que comprende un dominio catalitico del extremo c-terminal de npp1, una región fc de una inmunoglobulina y opcionalmente un resto de direccionamiento; ácido nucleico que lo codifica; vector; celula huesped. |
Country Status (10)
| Country | Link |
|---|---|
| US (7) | US8846603B2 (enExample) |
| EP (1) | EP2545080B1 (enExample) |
| JP (3) | JP5735665B2 (enExample) |
| BR (1) | BR112013023010B1 (enExample) |
| CL (1) | CL2013002607A1 (enExample) |
| ES (2) | ES2628841T3 (enExample) |
| NZ (1) | NZ615070A (enExample) |
| SG (2) | SG10202100341XA (enExample) |
| TR (1) | TR201903573T4 (enExample) |
| WO (1) | WO2011113027A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011113027A2 (en) | 2010-03-12 | 2011-09-15 | Synageva Biopharma Corp | Npp1 fusion proteins |
| RU2550961C2 (ru) | 2010-09-09 | 2015-05-20 | Синаджева Биофарма Корп. | Использование кислой лизосомной липазы для лечения дефицита кислой лизосомной липазы у больных |
| KR20140006037A (ko) | 2011-02-15 | 2014-01-15 | 시나게바 바이오파르마, 코포레이션 | 리소좀의 산 리파제 결핍을 치료하는 방법들 |
| AU2011362576B2 (en) * | 2011-03-11 | 2017-06-08 | Alexion Pharmaceuticals, Inc. | NPP1 fusion proteins |
| PL2956163T3 (pl) | 2013-02-13 | 2025-04-14 | Yale University | Kompozycje do leczenia patologicznego zwapnienia i kostnienia |
| EP3399317A1 (en) * | 2013-05-06 | 2018-11-07 | Bio-rad Laboratories, Inc. | Stabilization of labile analytes in reference materials |
| WO2016100803A2 (en) | 2014-12-19 | 2016-06-23 | Alexion Pharmaceuticals, Inc. | Methods of treating tissue calcification |
| MX391074B (es) | 2015-05-19 | 2025-03-21 | Univ Yale | Composiciones para el tratamiento de condiciones patológicas de calcificación y sus métodos de uso. |
| CA3005142A1 (en) | 2015-11-20 | 2017-05-26 | Yale University | Compositions for treating ectopic calcification disorders, and methods using same |
| EP3471747A1 (en) * | 2016-06-16 | 2019-04-24 | Alexion Pharmaceuticals, Inc. | Methods of treating myointimal proliferation |
| EP3493829B1 (en) | 2016-08-05 | 2024-04-17 | Yale University | Compositions and methods for stroke prevention in pediatric sickle cell anemia patients |
| US12134790B2 (en) | 2017-09-27 | 2024-11-05 | Inozyme Pharma, Inc. | Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1) |
| AU2019327572B2 (en) | 2018-08-31 | 2025-11-13 | Yale University | ENPP1 polypeptides and methods of using same |
| KR20230042263A (ko) | 2020-06-09 | 2023-03-28 | 이노자임 파마, 인코포레이티드 | 가용성 enpp1 또는 enpp3 단백질 및 이의 사용 |
| WO2025184419A1 (en) * | 2024-02-29 | 2025-09-04 | Kodiak Sciences Inc. | Engineered complement inhibitor proteins |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US6825396B2 (en) | 1996-06-12 | 2004-11-30 | Board Of Trustees Operating Michigan State University | Methods for tissue specific synthesis of protein in eggs of transgenic hens |
| US6455495B1 (en) | 1997-02-14 | 2002-09-24 | The Salk Institute For Biological Studies | Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents |
| US20040019923A1 (en) | 1997-10-16 | 2004-01-29 | Ivarie Robert D. | Exogenous proteins expressed in avians and their eggs |
| JP2001520009A (ja) | 1997-10-16 | 2001-10-30 | ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド | 鳥の導入遺伝子についてのマグナム特異的プロモーターを含むベクター |
| DK1032662T3 (da) | 1997-11-07 | 2006-07-03 | Trillium Therapeutics Inc | Fremgangsmåder og sammensætninger til immunmodulation |
| DE20121960U1 (de) | 2000-04-06 | 2004-01-15 | Epigenomics Ag | Nukleinsäuren für die Diagnose von mit Metastase assoziierten Krankheiten |
| US20020108132A1 (en) | 2001-02-02 | 2002-08-08 | Avigenics Inc. | Production of a monoclonal antibody by a transgenic chicken |
| US6875588B2 (en) | 2001-11-30 | 2005-04-05 | Avigenics, Inc. | Ovomucoid promoter and methods of use |
| US7294507B2 (en) | 2001-11-30 | 2007-11-13 | Avigenics, Inc. | Ovomucoid promoters and methods of use |
| US7858297B2 (en) | 2001-12-18 | 2010-12-28 | Centre National De La Recherche Scientifique Cnrs | Chemokine-binding protein and methods of use |
| AU2003213246A1 (en) | 2002-02-21 | 2003-09-09 | University Of Virginia Patent Foundation | Bone targeting peptides |
| US20050090001A1 (en) | 2003-10-07 | 2005-04-28 | Parker Stephen H. | Cell lines and methods for producing proteins |
| HUE055861T2 (hu) | 2004-04-21 | 2021-12-28 | Alexion Pharma Inc | Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez |
| US20060074225A1 (en) * | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
| GB0426397D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| US20090180989A1 (en) * | 2005-10-05 | 2009-07-16 | Synageva Biopharma Corp. | Compositions and methods for delivering nucleotide sequences to vertebrates |
| PL2158319T4 (pl) | 2007-05-11 | 2016-04-29 | Alexion Pharma Inc | Fosfataza alkaliczna kierowana do kości, zestawy i zastosowanie |
| PE20100141A1 (es) * | 2008-05-23 | 2010-02-22 | Wyeth Corp | Proteina de union al receptor de interleuquina 21 |
| WO2011113027A2 (en) | 2010-03-12 | 2011-09-15 | Synageva Biopharma Corp | Npp1 fusion proteins |
-
2011
- 2011-03-11 WO PCT/US2011/028233 patent/WO2011113027A2/en not_active Ceased
- 2011-03-11 EP EP11754231.6A patent/EP2545080B1/en active Active
- 2011-03-11 US US13/583,973 patent/US8846603B2/en active Active
- 2011-03-11 ES ES11754231.6T patent/ES2628841T3/es active Active
- 2011-09-15 SG SG10202100341XA patent/SG10202100341XA/en unknown
- 2011-09-15 BR BR112013023010-0A patent/BR112013023010B1/pt active IP Right Grant
- 2011-09-15 JP JP2013557704A patent/JP5735665B2/ja active Active
- 2011-09-15 NZ NZ615070A patent/NZ615070A/en not_active IP Right Cessation
- 2011-09-15 TR TR2019/03573T patent/TR201903573T4/tr unknown
- 2011-09-15 ES ES11861101T patent/ES2716526T3/es active Active
- 2011-09-15 US US14/004,294 patent/US20140154774A1/en not_active Abandoned
- 2011-09-15 SG SG10201500208SA patent/SG10201500208SA/en unknown
-
2013
- 2013-09-10 CL CL2013002607A patent/CL2013002607A1/es unknown
-
2014
- 2014-08-01 US US14/449,364 patent/US9540621B2/en active Active
- 2014-10-06 US US14/507,124 patent/US20150024460A1/en not_active Abandoned
-
2015
- 2015-04-16 JP JP2015084216A patent/JP6096826B2/ja active Active
-
2017
- 2017-01-27 US US15/417,590 patent/US20170145393A1/en not_active Abandoned
- 2017-02-16 JP JP2017026961A patent/JP6484905B2/ja active Active
-
2020
- 2020-11-25 US US17/105,245 patent/US20210301268A1/en not_active Abandoned
-
2022
- 2022-08-11 US US17/819,065 patent/US20230129977A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2545080B1 (en) | 2017-05-10 |
| US8846603B2 (en) | 2014-09-30 |
| US20170145393A1 (en) | 2017-05-25 |
| JP2015164427A (ja) | 2015-09-17 |
| ES2628841T3 (es) | 2017-08-04 |
| US20150024460A1 (en) | 2015-01-22 |
| ES2716526T3 (es) | 2019-06-13 |
| US20130273021A1 (en) | 2013-10-17 |
| US20140377859A1 (en) | 2014-12-25 |
| NZ615070A (en) | 2015-10-30 |
| WO2011113027A2 (en) | 2011-09-15 |
| BR112013023010A2 (pt) | 2018-07-03 |
| US9540621B2 (en) | 2017-01-10 |
| JP2014509851A (ja) | 2014-04-24 |
| BR112013023010B1 (pt) | 2022-05-10 |
| SG10202100341XA (en) | 2021-02-25 |
| EP2545080A2 (en) | 2013-01-16 |
| JP2017137318A (ja) | 2017-08-10 |
| JP5735665B2 (ja) | 2015-06-17 |
| US20210301268A1 (en) | 2021-09-30 |
| SG10201500208SA (en) | 2015-03-30 |
| JP6096826B2 (ja) | 2017-03-15 |
| US20230129977A1 (en) | 2023-04-27 |
| TR201903573T4 (tr) | 2019-04-22 |
| US20140154774A1 (en) | 2014-06-05 |
| EP2545080A4 (en) | 2013-09-11 |
| JP6484905B2 (ja) | 2019-03-20 |
| WO2011113027A3 (en) | 2012-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013002607A1 (es) | Polipeptido de fusion nucleotido pirofosfatasa/fosfodiesterasa 1 (npp1) que comprende un dominio catalitico del extremo c-terminal de npp1, una región fc de una inmunoglobulina y opcionalmente un resto de direccionamiento; ácido nucleico que lo codifica; vector; celula huesped. | |
| WO2013152351A3 (en) | Fusion polypeptides and methods of use thereof | |
| PH12018501280A1 (en) | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use | |
| EP3950941A3 (en) | Dnase polypeptide variants | |
| MX2023001834A (es) | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. | |
| EA201390666A1 (ru) | Cxcr2-связывающие полипептиды | |
| MX2023007211A (es) | Anticuerpos antimiostatina y metodos de uso. | |
| MX2017014125A (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
| WO2016066756A3 (en) | Protease variants and polynucleotides encoding same | |
| WO2016066757A3 (en) | Protease variants and polynucleotides encoding same | |
| WO2013006756A3 (en) | Alpha amylase variants and polynucleotides encoding same | |
| HK1203393A1 (en) | Chimeric antigen receptors targeting b-cell maturation antigen | |
| WO2015024739A3 (en) | Detergent composition comprising protease variants | |
| EP4219702A3 (en) | Enzyme variants and polynucleotides encoding the same | |
| CL2013001645A1 (es) | Secuencia de acido nucleico aislada que codifica un receptor de antigeno quimerico, el cual comprende un dominio de union a antigeno, un dominio transmembrana, una region de señalizacion coestimulatoria y un dominio de señalizacion cd3 zeta; dicho receptor; celula; vector; y su uso para tratar una enfermedad relacionada con la expresion elevada de un antigeno tumoral. | |
| WO2012146171A9 (en) | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same | |
| WO2013119302A3 (en) | Gh61 polypeptide variants and polynucleotides encoding same | |
| WO2013168108A3 (en) | Biparatopic binding polypeptides for cxcr2 and uses thereof | |
| EP3321360A3 (en) | Alpha-amylase variants and polynucleotides encoding same | |
| CA2852603C (en) | Alpha-amylase variants and polynucleotides encoding same | |
| WO2014195356A3 (en) | Alpha-amylase variants and polynucleotides encoding same | |
| MX2013010392A (es) | Proteinas de fusion npp1. | |
| MX382218B (es) | Variantes de lipasa y polinucleotidos que las codifican. | |
| MX2013003237A (es) | Variantes de polipeptidos que tienen actividad potenciadora celulolitica y polinucleotidos que codifican a los mismos. | |
| MX2013003236A (es) | Variantes de polipeptidos que tienen actividad potenciadora celulolitica y polinucleotidos que codifican a los mismos. |